Option chain shows key data for Evotec's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Evotec.

Evotec (NASDAQ:EVO) Stock, Option Chain

Evotec

Eaton Vance Ohio Municipal Income Trust Shares of Beneficial Interest

Eaton Vance Ohio Municip

Eaton Vance Ohio

Eaton Vance Ohio Municipal Income Trust

AMEX

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Expected Surge in M&A and IPO Activity

Biotech

Equities

News

Health Care

Movers

Trading Ideas

General

HALO

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec&#39;s value to €2 billion. The merger aims to enhance Halozyme&#39;s revenue growth and portfolio.

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

Rumors

Media

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the company.

Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal

xr:d:DAFqZwXnoXk:2,j:7421204755476627396,t:23080215

Pre-Market Outlook

Markets

EXAS

FSLR

GEVO

NOVA

OSCR

PACS

SMCI

Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec SE

EVO TRANSPORTATION by EVO Transportation & Energy Services, Inc.

EVO Transportation & Energy Services Inc

EVOAIR HOLDINGS INC by EvoAir Holdings Inc.

EvoAir Holdings Inc

EvoAir Holdings Inc Ordinary Shares

Evoke Pharma Inc

SYMBOLIC LOGIC INC by Symbolic Logic Inc.

Symbolic Logic Inc

WIIM

Evotec shares are trading higher after Halozyme Therapeutics confirmed a cobmination offer.

On Thursday, Halozyme Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) submitted a non-binding proposal to Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) to acquire the German company for 11.00 euros per share in cash, implying a fully diluted <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41989694/halozyme-confirms-proposal-to-combine-with-evotec-for-11-00-per-share-in-an-all-cash-transaction" rel="noreferrer noopener">equity value of 2.0 billion euros</a> (around $2.11 billion).
The proposal represents a premium of 109% to Evotec&#8217;s undisturbed share price on&nbsp;October 15, 2024, the day before Triton Partners&#8217; initial accumulation of Evotec shares.
Evotec&nbsp;<a target="_blank" href="https://www.evotec.com/en/about-us/evotec" rel="noreferrer noopener">offers</a> drug discovery and development services to several biotech and pharmaceutical companies.
&#8220;The combination of Halozyme and Evotec would diversify and extend Halozyme revenue and EBITDA growth and durability well into the next decade and beyond,&#8221; said&nbsp;Helen Torley, president and chief executive officer of Halozyme.
Halozyme said its strong cash flow would enable ongoing investments in Evotec&#8217;s early-stage programs and new technologies.
The proposed&nbsp;combination&nbsp;is expected to significantly expand and diversify Halozyme&#8217;s revenue and EBITDA over the next decade. The combined technology offerings would open up new partnership opportunities and program expansions.
Earlier this week, a Bloomberg report highlighted that private equity firm Triton Partners&nbsp;was also considering acquiring Evotec. In an SEC filing, Evotec&nbsp;reported&nbsp;that Triton had acquired a 9.99% stake in the company via several <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41882329/private-equity-triton-partners-takes-around-10-stake-in-evotec-reportedly-mulls-potential-takeover-deal" rel="noreferrer noopener">open-market transactions</a>.
During its second-quarter earnings release, Evotec&nbsp;disclosed it identified a headcount reduction potential of approximately 400 roles (7% of the&nbsp;workforce) across the global footprint and a reduction of the physical footprint by surrendering <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40376143/bristol-myers-german-partner-evotec-plans-layoffs-cites-challenging-revenues-profitability" rel="noreferrer noopener">certain lease agreements</a>.
Evotec&nbsp;exited gene therapy and closed a site in Orth, Austria. It also shut down chemistry activities in Lyon, France, and separated a manufacturing facility in Halle/Westphalia, Germany.
Recently, Halozyme reported third-quarter 2024 revenue of $290.1 million, compared to&nbsp;$216.0 million&nbsp;in the third quarter of 2023.
While announcing its third quarter results, Halozyme raised the fiscal year 2024 adjusted EPS guidance to $4.00-$4.20 from $3.65-$4.05&nbsp;(current consensus $4.15) and revenue guidance to $970 million—$1.02 billion from $935 million—$1.015 billion (current <a href="https://www.benzinga.com/pressreleases/24/10/n41663735/halozyme-reports-third-quarter-2024-financial-and-operating-results" target="_blank" rel="noreferrer noopener">consensus of $1.003 billion</a>).
Evotec <a href="https://www.benzinga.com//node/41994208">responded</a> that it would thoroughly evaluate this expression of interest, determine the appropriate next steps, and communicate its decisions to the capital market in compliance with legal requirements.
Price Action: HALO stock is down 14.8% at $45.97 and EVO stock is up 8.43% at $5.53 at last check Friday.
Image via Pexels
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers" target="_blank" rel="noreferrer noopener">European And US Vaccine Stocks Are Under Pressure &#8211; Here&#8217;s Why</a></li>
</ul>

The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.

Evotec Confirms Receipt Of Non-binding Expression Of Interest From Halozyme Therapeutics With An Offer Price Of EUR 11.00 Per Share

Evotec shares are trading higher after the company announced it received a proposal to be acquired by Halozyme for approximately $2.1 billion.

Halozyme Confirms Proposal To Combine With Evotec For €11/Share All-Cash Transaction

Evotec Shares Resume Trade

Evotec Shares Halted To The Upside; Stock Now 10.33%

Evotec Is Said To Attract Takeover Interest From Halozyme

<h3>Gainers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock rose 175.6% to $0.19 during Monday's pre-market session. The market value of their outstanding shares is at $28.9 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 27.07% to $2.3. The company's market cap stands at $4.2 million. As per the press release, Q3 earnings came out today. </li>
<li>RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) shares increased by 22.7% to $89.0. The market value of their outstanding shares is at $6.5 billion. The company's, Q3 earnings came out today. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares increased by 21.95% to $1.0. The company's market cap stands at $3.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares increased by 21.28% to $4.33. The market value of their outstanding shares is at $171.6 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares increased by 19.37% to $4.93. The company's market cap stands at $1.7 billion. As per the news, the Q3 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares declined by 48.1% to $1.5 during Monday's pre-market session. The company's market cap stands at $52.3 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares decreased by 17.3% to $1.1. The company's market cap stands at $26.9 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 15.55% to $0.34. The market value of their outstanding shares is at $2.1 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 13.73% to $3.71. The company's market cap stands at $4.9 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock decreased by 10.68% to $178.2. The market value of their outstanding shares is at $314.6 billion. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares fell 8.46% to $2.6. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

CERO

DWTX

FRES

NUWE

RAPT

RDNT

REVB

SNES

TIVC

VIGL

12 Health Care Stocks Moving In Monday's Pre-Market Session

Evotec shares are trading higher following a report suggesting Triton Partners has taken a stake in the company and is considering a potential takeover deal.

Germany-based Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is trading on Monday after a report that suggests the company is a takeover target.
The private equity firm Triton Partners&nbsp;is reportedly considering acquiring Evotec, Bloomberg reported, citing people familiar with the matter.
In an SEC filing, Evotec <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1412558/000119312524254399/d872020dsc13d.htm" rel="noreferrer noopener">reported</a> that Triton had acquired a 9.99% stake in the company via several open-market transactions.
The company <a target="_blank" href="https://www.evotec.com/en/about-us/evotec" rel="noreferrer noopener">offers</a> drug discovery and development services to several biotech and pharmaceutical companies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41048867/novo-nordisk-and-evotec-collaborate-on-stem-cell-based-therapy-development" rel="noreferrer noopener">Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development</a>
According to the report, the investment firm has been trying to meet with senior Evotec executives as it looks into a possible buyout.
If Triton wants to increase its stake to 10% or more, it would need approval for foreign investment, the <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-11-11/triton-is-said-to-weigh-takeover-deal-for-drug-developer-evotec" rel="noreferrer noopener">report</a> added.
Any major move would also require backing from Evotec&#8217;s key shareholders, including Novo Holdings, the parent company of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and the Abu Dhabi-based Mubadala Investment.
Last week, the German company reported third-quarter revenues of 184.89 million euros, down from 196.28 million a year ago, <a target="_blank" href="https://www.evotec.com/uploads/download-files/IR-ESG-DE/2024-11-06_9M_Analyst-call-presentation.pdf" rel="noreferrer noopener">noting</a> a soft market in shared R&amp;D.
It <a target="_blank" href="https://www.evotec.com/uploads/download-files/IR-ESG/Financial_Publications/Interim-Statement-9M-2024-English.pdf" rel="noreferrer noopener">reported</a> an operating loss of 26.46 million euros, compared to 12.19 million euros loss a year ago.
In its second-quarter earnings, Evotec&#8217;s CEO said the company is operating in a more challenging market environment, notably the slowdown of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40376143/bristol-myers-german-partner-evotec-plans-layoffs-cites-challenging-revenues-profitability" rel="noreferrer noopener">early-stage R&amp;D spending</a>.
In October, Evotec announced advancements in its strategic partnership with&nbsp;Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which is&nbsp;focused on developing a molecular <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41490865/why-is-evotec-stock-gaining-today" rel="noreferrer noopener">glue-based pipeline</a>.
Price Action: EVO stock is up 16.2% at $4.80 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41877517/ge-healthcare-and-deephealth-team-up-to-advance-ai-powered-breast-cancer-screening" target="_blank" rel="noreferrer noopener">GE HealthCare And DeepHealth Team Up To Advance AI-Powered Breast Cancer Screening: Details</a></li>
</ul>

Evotec shares are trading higher. HC Wainwright & Co. Reiterated a Buy rating on the stock.

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) with a Buy and maintains $8 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Evotec, Maintains $8 Price Target

Evotec SE shares are trading lower after the company reported worse-than-expected Q3 financial results.

U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday.
Shares of Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue <a href="https://www.benzinga.com/general/biotech/24/11/41760212/exact-sciences-stock-plummets-after-worse-than-expected-q3-results-fy24-guidance-below-estimates">guidance below estimates</a>.
Exact Sciences reported quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million missed the consensus estimate of $717.66 million.
Exact Sciences shares dipped 27% to $52.20 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 24.3% to $20.97 in pre-market trading after the company lowered its financial outlook. The company expects to report first-quarter revenue of $5.9 billion to $6 billion, down from its previous guidance range of $6 billion to $7 billion. The company anticipates adjusted earnings of 75 cents to 76 cents per share, versus its previous guidance of 67 cents to 83 cents per share.</li>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) fell 20.8% to $1.86 in today's pre-market trading.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 20.1% to $5.64 in pre-market trading after gaining 8% on Tuesday.</li>
<li>PACS Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares fell 18.8% to $24.00 in pre-market trading after the company announced postponement of third-quarter results and disclosure on civil investigative demands from the federal government.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 18.6% to $13.76 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) declined 16.8% to $3.81 in pre-market trading following weak quarterly results.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares fell 16.8% to $15.25 in pre-market trading.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares fell 14.7% to $184.00 in pre-market trading.</li>
<li>The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) declined 9.9% to $13.97 in pre-market trading.</li>
<li>Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) shares fell 7.4% to $28.05 in pre-market trading as the company said profits fell around 20% in the first half of the fiscal year.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) stock increased by 16.6% to $10.4 during Wednesday's pre-market session. The market value of their outstanding shares is at $514.0 million. As per the press release, Q3 earnings came out today. </li>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) shares increased by 15.83% to $6.0. The market value of their outstanding shares is at $642.8 million. </li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares increased by 15.11% to $4.34. The company's market cap stands at $272.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Xylo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) stock rose 14.4% to $3.97. The market value of their outstanding shares is at $7.5 million. </li>
<li>Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) shares moved upwards by 13.77% to $85.99. The market value of their outstanding shares is at $11.6 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock increased by 13.63% to $1.25. The company's market cap stands at $4.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock decreased by 26.6% to $52.5 during Wednesday's pre-market session. The company's market cap stands at $9.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares declined by 24.53% to $0.1. The company's market cap stands at $1.7 million. </li>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) stock declined by 21.16% to $0.41. The market value of their outstanding shares is at $1.5 million. </li>
<li>PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares decreased by 20.49% to $23.49. The market value of their outstanding shares is at $3.6 billion. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock fell 19.66% to $3.68. The company's market cap stands at $1.3 billion. As per the press release, Q3 earnings came out today. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares declined by 15.93% to $0.41. The market value of their outstanding shares is at $5.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

BNOX

CYTO

GMED

MGNX

PCSA

RGNX

TNGX

XYLO

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BUSINESS OUTLOOK FOR FULL-YEAR 2024 CONFIRMED } Group revenues expected in the range of € 790 – 820 m (2023: € 781.4 m).&nbsp; &nbsp;R&amp;D expenditures are expected in a range of € 50 – 60 m (2023: € 64.8 m).&nbsp; &nbsp;Adjusted Group EBITDA is expected to reach € 15 – 35 m (2023: € 66.4 m).

Earnings

Guidance

Evotec Reaffirms 2024 Outlook: Revenues Of €790M-€820M, And Adjusted Group EBITDA Of €15M-€35M

Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 21 percent. This is a 0.83 percent decrease over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $203.213 million which missed the analyst consensus estimate of $208.977 million by 2.76 percent. This is a 4.88 percent decrease over sales of $213.639 million the same period last year.

Earnings Misses

Evotec Q3 2024 GAAP EPS $(0.12) Misses $(0.10) Estimate, Sales $203.213M Miss $208.977M Estimate

Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Evotec will report an earnings per share (EPS) of $-0.08.
Anticipation surrounds Evotec's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $0.23, leading to a 3.63% drop in the share price the following trading session.
Here's a look at Evotec's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.100</td>
<td>-0.03</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.29</td>
<td>-0.065</td>
<td></td>
<td>-0.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<h3>Evotec Share Price Analysis</h3>
Shares of Evotec were trading at $4.4 as of November 04. Over the last 52-week period, shares are down 50.7%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Evotec</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Evotec.
Analysts have provided Evotec with 2 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $5.9, suggesting a potential 34.09% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of 10x Genomics, BioLife Solns and Maravai LifeSciences, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Outperform trajectory for 10x Genomics, with an average 1-year price target of $24.75, indicating a potential 462.5% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for BioLife Solns, with an average 1-year price target of $29.0, implying a potential 559.09% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Maravai LifeSciences, with an average 1-year price target of $10.17, suggesting a potential 131.14% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for 10x Genomics, BioLife Solns and Maravai LifeSciences, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fortrea Holdings</td>
<td>Neutral</td>
<td>-8.65%</td>
<td>$137.10M</td>
<td>-9.07%</td>
</tr>
<tr>
<td>10x Genomics</td>
<td>Outperform</td>
<td>-1.30%</td>
<td>$106.39M</td>
<td>-4.94%</td>
</tr>
<tr>
<td>BioLife Solns</td>
<td>Buy</td>
<td>-3.11%</td>
<td>$14.89M</td>
<td>-6.33%</td>
</tr>
<tr>
<td>Maravai LifeSciences</td>
<td>Neutral</td>
<td>6.51%</td>
<td>$35.13M</td>
<td>-1.79%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Evotec ranks in the middle among its peers for Consensus rating. It is at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity.
<h3>Unveiling the Story Behind Evotec</h3>
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&amp;D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
<h3>Evotec: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Evotec showcased positive performance, achieving a revenue growth rate of 6.96% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -52.13%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Evotec's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.96%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Evotec's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.51%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.
<a href="https://www.benzinga.com/quote/EVO/earnings">To track all earnings releases for Evotec visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Evotec's Upcoming Earnings

<ul>
<li>Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners</li>
<li>Transaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth drivers</li>
<li>New ownership committed to maintaining and growing the business</li>
</ul>

Evotec Divests API Manufacturing Site To Monacum Partners As Part Of Strategic Focus Shift; Terms Not Disclosed

Key deals this week: Exxon, Unilever, Cardinal Health, Charter Communications and more

Halozyme plans to finance $2.1 takeover of Evotech in cash: report

Halozyme plans to finance $2.1B takeover of Evotech in cash: report

Deutsche Bank analyst Falko Friedrichs maintained a Sell rating on Evotec (0IRF – Research Report) today and set a price target of €4.00. The compa...

Deutsche Bank  Remains a Sell on Evotec (0IRF)

Halozyme Therapeutics (HALO) provided an update on its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash, implying a ...

Halozyme provides update on proposal to combine with Evotec

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Spirit Airlines (SAVE) has entered int...

Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz

Evotec plunges amid report it's against Halozyme Therapeutics takeover

Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal

Franklin International Growth Equity ADR SMA Q3 2024 Commentary

Franklin International Growth Fund Q3 2024 Commentary

ASML

ASMLF

BIIB

BTBT

CEVMF

CEVMY

CHTR

CPRI

CYBR

DISPF

DSCSY

DSDVF

DSDVY

DSKYF

DSNKY

EONR

EVOTF

EXPGF

EXPGY

GMAB

GNMSF

HIMS

HOOD

HSBC

HUMA

ICGUF

INGM

JTKWY

KXSCF

LBRDA

LBRT

LUKOY

MELI

MGIC

NFLX

NVDA

NVEI

PMMAF

PUMSY

ROKU

SAVE

SHOP

SKFOF

SXYAY

TSLA

TWST

Press Releases

Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery

Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)

Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies

Evotec and Bristol Myers Squibb Expand Proteomics Partnership

Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

Evotec Announces Sale of API Manufacturing Facility to Monacum Partners

Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Comments

Evotec

Evotec (EVO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga